© Reuters. FILE PHOTO: A logo of a testing company Qiagen is seen as Economy Minister Andreas Pinkwart and Health Minister Karl-Josef Laumann of the German state Northrhine Westphalia visit Qiagen’s facility, in Hilden, Germany, September 8, 2020. REUTERS/Leon Kuege
(Reuters) – California-based diagnostics company Bio-Rad Laboratories (NYSE:) is in talks to merge with Qiagen (NYSE:) NV, the Wall Street Journal reported on Monday, citing people familiar with the matter.
Talks between the two companies have been going on for a while but an agreement unlikely for another few weeks, the report said.
Bio Rad, which manufactures and supplies products such as laboratory apparatus, instruments and diagnostics, has a market cap of $12.85 billion.
Both Qiagen and Bio-Rad did not immediately respond to Reuters’ requests for comments.
Be the first to comment